Skip Navigation


Annals of Oncology Advance Access originally published online on September 5, 2007
Annals of Oncology 2007 18(11):1834-1841; doi:10.1093/annonc/mdm343
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/11/1834    most recent
mdm343v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agis, H.
Right arrow Articles by Valent, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agis, H.
Right arrow Articles by Valent, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

hematologic malignancies

Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)

H. Agis1, W. R. Sperr1, S. Herndlhofer1, H. Semper1, H. Pirc-Danoewinata2, O. A. Haas2, C. Mannhalter3, H. Esterbauer3, K. Geissler4, C. Sillaber1, U. Jäger1 and P. Valent1,*

1 Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence for Clinical and Experimental Oncology (CLEXO), Medical University of Vienna
2 Children's Cancer Research Institute (CCRI), Vienna
3 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna
4 Department of Internal Medicine V, Hospital Hietzing, Vienna, Austria

* Correspondence to: Dr P. Valent, M.D. Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria, Tel: + 43 1 40400 -5488/-6086/-6085, Fax: + 43 1 40400 4030; E-mail: peter.valent{at}meduniwien.ac.at

Background: Although imatinib is highly effective in chronic myeloid leukemia (CML), drug-resistance may occur. Therefore, monitoring of minimal residual disease (MRD) during treatment with imatinib is important. However, most MRD-parameters are expensive and require special technology. We determined the value of histamine as MRD-marker in CML.

Patients and methods: Histamine levels were measured serially in whole blood samples before and during imatinib therapy in 80 CML patients by radioimmunoassay.

Results: Histamine levels were highly upregulated in CML at diagnosis compared to healthy controls, and correlated with the presence of basophils. During treatment with imatinib, histamine levels decreased and returned to normal levels in those achieving a complete cytogenetic response (CCR). Loss of CCR during therapy was invariably accompanied by an increase in histamine. Moreover, a histamine level of >100 ng/ml three or six months after start of imatinib was associated with a significantly reduced probability of survival (p<0.05). Whereas basophils were found to correlate well with histamine during imatinib, no correlations were found between histamine and Ph+ metaphases or histamine and BCR/ABL.

Conclusion: Histamine-monitoring during treatment with imatinib is of prognostic significance.

Key words: basophils, CML, histamine, imatinib, MRD


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2007 18: 1757. [Extract] [Full Text]  





Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.